BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

HRV Pharma invests Rs 150 Cr to expand peptide and high-potent API capabilities

07 September 2026 | News

To strengthen HRV Pharmaâ??s presence in high-value pharmaceutical segments while retaining its asset-light operating model

Hyderabad-based HRV Pharma, a global asset-light pharmaceutical platform, has announced strategic investments to expand its capabilities across two high-value and supply-constrained pharmaceutical segments, synthetic peptides and high-potency oncology APIs.

These initiatives are designed to strengthen HRV's portfolio of complex molecules, accelerate access to regulated markets, and create dedicated supply capabilities while continuing to operate through its asset-light business model.

HRV Pharma is investing as part of a combined Rs 40 to Rs 50 crore programme to establish dedicated cGMP peptide manufacturing capacity through a strategic capacity underwriting arrangement. The initiative will focus on commercial-stage and new-to-generic synthetic peptides across multiple therapeutic areas, with HRV retaining ownership of regulatory assets, product IP, and global commercialisation rights.

The capacities are currently scaling rapidly and are expected to be ready in the next 6-8 months, giving HRV Pharma the opportunity to address a totally addressable market of more than $2 billion.

The company is establishing a strategic joint venture with a focus on high-potency oncology APIs and specialised molecules, with an investment commitment of approximately Rs 100 crore. The platform will create specialised capabilities for developing and commercialising high-potent APIs, initially focusing on oncology and niche therapeutic segments where supply capabilities remain highly specialised.

The peptide capacity initiative will support the development and commercialisation of commercial-stage and new-to-generic synthetic peptides across regulated markets including the US, Europe, and other global regions. The platform is expected to develop 20–30 oncology and high-potent APIs in phases, beginning with R&D capabilities and regulatory filings, followed by dedicated commercial-scale capabilities.